Compare BioNano Genomics Inc (BNGO) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Vanguard Information Technology Index Fund ETF trades at $115.62. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | VGT | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | — |
52-Week High | $4.92 | $125.77 |
52-Week Low | $1.09 | $83.59 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
VGT trades at $115.58, down 2.12% on the day amid a neutral technical signal. The ETF's moving averages show bearish momentum, while oscillators are neutral. Recent news highlights strong 2026 performance against the S&P 500 and ongoing investor interest in tech ETFs, though fee comparisons with competitors like FTEC are noted. A 1:8 stock split occurred in April 2026, with a small dividend scheduled for June 2026.
Outlook remains tied to tech sector strength and AI-driven earnings, but risks include valuation sensitivity and sector volatility. The ETF's low expense ratio and broad diversification offer a cost-effective tech exposure, yet overlap costs and hyperscaler capex guidance in H2 2026 warrant monitoring for potential pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
